Prof Peter Albers speaks to ecancer about the results from the PROBASE trial. Digital rectal examination (DRE), in most guidelines, is a recommended screening tool for early prostate cancer detection.

PROBASE is a randomised screening trial that has accrued younger men to test a risk-adapted screening strategy using a baseline prostate specific antigen value with the additional offer of DRE in a large sub-cohort of participants.

Prof Albers says that the trial showed that DRE is not useful as a solitary screening tool for prostate cancer in young men. He says the results from Stockholm3 and PROBASE trials can prove beneficial in the field of prostate cancer screening.